NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
This grant aims to bridge funding gaps in developing biomedical products for heart, lung, blood, and sleep disorders in small commercial markets through SBIR Phase IIB awards.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health (NIH)
Due Dates: November 17, 2025
Funding Amounts: Award size and duration vary; contact program for details. No cost-sharing required.
Summary: Supports small businesses in advancing late-stage SBIR-funded technologies for heart, lung, blood, and sleep disorders in small markets toward commercialization and regulatory approval.
Key Information: Only U.S. small businesses with prior SBIR/STTR Phase II awards are eligible; projects must target rare diseases or pediatric populations and require eventual federal regulatory approval.
Description
This opportunity, offered by the National Heart, Lung, and Blood Institute (NHLBI) under the NIH Small Business Innovation Research (SBIR) program, aims to help small businesses bridge the funding gap between SBIR Phase II support and commercialization for products addressing rare diseases or young pediatric populations (ages 0–12) related to heart, lung, blood, and sleep disorders. The program specifically targets products that require eventual federal regulatory approval and are being developed for small commercial markets, such as rare diseases or pediatric indications. The funding supports further research and development (Phase IIB) of promising technologies previously funded by SBIR or STTR Phase II awards, with the goal of advancing these products toward regulatory approval and commercialization, often in partnership with third-party investors or strategic partners.
